Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE American: VNRX) priced a public offering of 2,960,000 common shares plus warrants for up to 1,480,000 shares at a combined price of $1.55 per share and half warrant, for expected gross proceeds of about $4.6 million before fees.
Warrants are immediately exercisable at $1.55 per share for five years and could add about $2.3 million in gross proceeds if fully exercised. The offering, placed by Maxim Group, is expected to close on June 9, 2026, subject to customary conditions.
Volition (NYSE AMERICAN: VNRX) filed a new patent application to protect use of its Nu.Q® NETs test for triaging and monitoring patients suspected of Ebola infection.
The CE-Marked automated assay and a finger-prick LFT prototype target frontline use in outbreak zones, with Volition actively seeking global strategic partners.
Volition (NYSE AMERICAN: VNRX) reported strong commercial and clinical progress across multi-billion-dollar markets. Q1 2026 revenue reached $1 million, a 300% year-over-year increase, supported by momentum in cancer detection, companion animal health, and sepsis/NETosis applications.
Highlights include a Capture-Seq™ cancer manuscript with >95% sensitivity and 95% specificity in early-stage cancers, a Nu.Q® Vet feline lymphoma study expected to unlock a $5 million milestone upon publication, inclusion of Nu.Q® NETs in the $7.3 million DETECSEPS sepsis program, and progress toward French reimbursement for lung cancer testing. Volition cites annualized TAMs of $23B for Capture-Seq™ cancer detection, $3.8B for Nu.Q® NETs, and $1.0B+ for Nu.Q® Vet canine/feline.
Volition (NYSE AMERICAN: VNRX) reported first quarter 2026 revenue of approximately $1.0 million, up from $0.2 million in 2025, with operating loss down 3%.
Net cash used in operations was $5.3 million. The company raised $5.4 million via its at-the-market facility, $1.9 million from a convertible note and warrant, and received $1 million in non-dilutive Walloon funding, with about $0.9 million more expected over 12 months.
Volition highlighted progress across Nu.Q® Vet (including a feline lymphoma assay manuscript linked to a potential $5 million milestone), Nu.Q® Lung Cancer reimbursement work, and new potential Nu.Q® NETs use cases in acute trauma risk identification and Hidradenitis Suppurativa.
VolitionRx (NYSE AMERICAN: VNRX) will host its first quarter 2026 earnings and business update conference call on Friday, May 15, 2026 at 8:30 a.m. U.S. Eastern Time (2:30 p.m. CET). Senior management will review financial and operating results, key events, and upcoming milestones, with live webcast and replay available.
Volition (NYSE AMERICAN: VNRX) submitted a peer‑review manuscript reporting the Nu.Q® Vet Feline prototype assay detected 86% of feline lymphomas at 97% specificity.
The company says publication is expected to trigger a $5 million contractual milestone and aims to commercialize a blood-based feline cancer screening test via labs and point-of-care channels.
Volition (NYSE AMERICAN: VNRX) announced successful detection of nucleosomes in capillary (finger-prick) blood from ICU sepsis patients using a lateral flow prototype. The study, part of the SUMMIT program, showed feasibility of bedside or home point-of-care testing and referenced prior correlation with venous samples and the automated Nu.Q laboratory assay. Management said the device could enable quantitative, rapid nucleosome readouts and expand access in low-income countries via NGO and strategic partnerships. The company cited an estimated 166 million global sepsis cases as the addressable market.
VolitionRx (NYSE AMERICAN: VNRX) announced that on April 22, 2026 the NYSE American accepted its plan of compliance to regain listing standards. The company has until August 6, 2027 to restore required stockholders' equity thresholds and will undergo periodic reviews during the Plan Period.
The Acceptance Letter does not affect current listing or the company's SEC reporting obligations.
Volition (NYSE AMERICAN: VNRX) launched the rNuQ™ webshop on April 20, 2026, selling ready-to-use recombinant nucleosomes developed over the past 10 years.
Manufactured in an ISO 13485 facility, products ship at +4 °C in a glycerol-free buffer. The move expands Nu.Q® Discover commercialisation after 86% revenue growth in 2025 and ~100 clients worldwide.
VolitionRx (NYSE AMERICAN: VNRX) reported full fiscal year 2025 results and a business update on March 31, 2026. Key metrics: 2025 revenue $1.7M (+40% YoY), Q4 revenue growth +133% YoY, operating expenses down $4.8M (17%), net loss down 14%, and net cash used in operations $19.7M (down 24%).
Post-year-end financings included $5.4M ATM proceeds, a $1.9M convertible note and warrant, and $1M non-dilutive regional funding with ~$0.9M conditional tranches expected.